Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC4419 in Critical COVID-19
NCT04555096Phase 2Terminated
- Sponsor
- Galera Therapeutics, Inc.
- Start
- Sep 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avasopasem manganese in coronavirus disease 2019 (COVID-19), sponsored by Galera Therapeutics, Inc.. Started Sep 2020; status: terminated.
02
Drugs
avasopasem manganese
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04555096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04555096.